465 related articles for article (PubMed ID: 34017093)
1. Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
Kow CS; Ming LC; Hasan SS
Hypertens Res; 2021 Aug; 44(8):1042-1045. PubMed ID: 34017093
[No Abstract] [Full Text] [Related]
2. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Koshy AN; Murphy AC; Farouque O; Ramchand J; Burrell LM; Yudi MB
Intern Med J; 2020 Dec; 50(12):1468-1474. PubMed ID: 33191600
[TBL] [Abstract][Full Text] [Related]
3. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population.
Sattar Y; Mukuntharaj P; Zghouzi M; Suleiman AM; Attique H; Ullah W; Sana MK; Zaher N; Mehmood M; Doshi RP; Panchal A; Mir T; Nadeem M; Ali OE; Mohamed M; Bagur R; Elgendy IY; Mamas MA; Alraies MC
High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):405-416. PubMed ID: 34181203
[TBL] [Abstract][Full Text] [Related]
5. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
7. COVID-19 and inhibitors of the renin-angiotensin-aldosterone system.
Hussain M; Jabeen Q; Ahmad FU; Kashif-Ur-Rehman ; Fatima M; Shaukat S; Majeed A; Barkat MQ; Wu X
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):815-816. PubMed ID: 33198546
[No Abstract] [Full Text] [Related]
8. The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.
Harky A; Chor CYT; Nixon H; Jeilani M
J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320320987118. PubMed ID: 33412991
[No Abstract] [Full Text] [Related]
9. Renin-Angiotensin-Aldosterone System Inhibitors and the Risk of AKI in COVID-19 Compared with Influenza.
Birkelo BC; Parr SK; Perkins AM; Greevy RA; Arroyo JP; Hung AM; Vincz AJ; Shah SC; Kapoor T; Matheny ME; Siew ED
Clin J Am Soc Nephrol; 2022 Mar; 17(3):423-425. PubMed ID: 35110376
[No Abstract] [Full Text] [Related]
10. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
11. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
12. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
Tadic M; Cuspidi C
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
[No Abstract] [Full Text] [Related]
13. Drugs and the renin-angiotensin system in covid-19.
Aronson JK; Ferner RE
BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
[No Abstract] [Full Text] [Related]
14. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
[TBL] [Abstract][Full Text] [Related]
15. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
[No Abstract] [Full Text] [Related]
16. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW
Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294
[TBL] [Abstract][Full Text] [Related]
17. Association between early worsening of kidney function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis.
Yuan S; Liu Y; He W; Jin J; Liu L; He Q
Nephrology (Carlton); 2021 Oct; 26(10):772-781. PubMed ID: 34165226
[TBL] [Abstract][Full Text] [Related]
18. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
Makani H; Bangalore S; Desouza KA; Shah A; Messerli FH
BMJ; 2013 Jan; 346():f360. PubMed ID: 23358488
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
